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An unexpected role for a Wnt-inhibitor: Dickkopf-1
triggers a novel cancer survival mechanism through
modulation of aldehyde-dehydrogenase-1 activity
U Krause1,2, DM Ryan3, BH Clough1 and CA Gregory*,1
It is widely accepted that canonical Wnt (cWnt) signaling is required for the differentiation of osteoprogenitors into osteoblasts.
Furthermore, tumor-derived secretion of the cWnt-antagonist Dickkopf-1 (Dkk-1) is known to cause bone destruction, inhibition
of repair and metastasis in many bone malignancies, but its role in osteosarcoma (OS) is still under debate. In this study,
we examined the role of Dkk-1in OS by engineering its overexpression in the osteochondral sarcoma line MOS-J. Consistent with
the known role of Dkk-1 in osteoblast differentiation, Dkk-1 inhibited osteogenesis by the MOSJ cells themselves and also in
surrounding tissue when implanted in vivo. Surprisingly, Dkk-1 also had unexpected effects on MOSJ cells in that it increased
proliferation and resistance to metabolic stress in vitro and caused the formation of larger and more destructive tumors than
controls upon orthotopic implantation. These effects were attributed in part to upregulation of the stress response enzyme and
cancer stem cell marker aldehyde-dehydrogenase-1 (ALDH1). Direct inhibition of ALDH1 reduced viability under stressful culture
conditions, whereas pharmacological inhibition of cWnt or overexpression of ALDH1 had a protective effect. Furthermore, we
observed that ALDH1 was transcriptionally activated in a c-Jun-dependent manner through a pathway consisting of RhoA, MAP-
kinase-kinase-4 and Jun N-terminal Kinase (JNK), indicating that noncanonical planar cell polarity-like Wnt signaling was the
mechanism responsible. Together, our results therefore demonstrate that Dkk-1 enhances resistance of OS cells to stress by
tipping the balance of Wnt signaling in favor of the non-canonical Jun-mediated Wnt pathways. In turn, this results in
transcriptional activation of ALDH1 through Jun-responsive promoter elements. This is the first report linking Dkk-1 to tumor
stress resistance, further supporting the targeting of Dkk-1 not only to prevent and treat osteolytic bone lesions but also to
reduce numbers of stress-resistant tumor cells.
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Osteosarcoma (OS) is a tumor of bone that usually affects
children. Approximately 3000 new cases were estimated in
the United States in 2012.1 Although it is a diverse disease
with multiple histological and clinical subtypes, the main
hallmark of OS is the aberrant osteoblastic and/or chondro-
genic differentiation of mesenchymal stem cells (MSCs).
One of the key mechanisms for control of MSC proliferation
and differentiation is the canonical Wnt-signaling (cWnt)
pathway.2,3 In this pathway, Wnt ligands bind to receptors
frizzled (Frz) and low-density lipoprotein receptor-related
protein (LRP) 5/6. The co-receptor complex recruits the
cytoplasmic protein disheveled (Dsh) to initiate a cytoplasmic
cascade resulting in the inhibition of glycogen-synthetase-
kinase-3b (GSK3b). With GSK3b sequestered in an inactive
form, phosphorylation and proteosomal degradation of the co-
transcription factor b-catenin are inhibited resulting in raised
cytosolic levels. Upon entry into the nucleus, b-catenin acts as
a nuclear enhancing factor and promotes osteogenic differen-
tiation. One of the most potent extracellular inhibitors of
cWnt-signaling is Dickkopf-1 (Dkk-1), and, when present in
high concentrations, bone homeostasis shifts in favor of the
catabolic axis.4 Indeed, high serum levels of Dkk-1 were
linked to increased osteolysis in multiple myeloma5 and were
found in sera of patients newly diagnosed with OS.6
Furthermore, Dkk-1 has been reported to have a role in the
engraftment of metastatic cells to bone in prostate and breast
cancer.7,8
Contrary to established literature supporting cWnt-signaling
as oncogenic,9 the roles of Wnts and their inhibitors are
controversial in bone tumors with a growing body of evidence,
suggesting that Wnt inhibition can exacerbate OS. For example,
inactive cWnt-signaling has been correlated to malignancy,10
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MSC transformation11 and prostate cancer metastasis.12
In contrast, inactive or inhbited cWnt-signaling has been
reported to decrease tumorigenesis and metastasis.13–16
In an attempt to resolve these controversies, we speculated
that Wnt-inhibitors exert contrasting effects on the tumor and
surrounding stroma. Specifically, they may slow tumor cell
proliferation, but their potent osteo-inhibitory effects on the
stroma could exert a protective effect by maintaining the tumor
niche. To this end, we examined the effects of the Wnt-
inhibitor Dkk-1 on the phenotype of the well-differentiated and
modestly malignant murine osteochondrosarcoma cell line
MOS-J.17
We stably introduced a single gene, human Dkk-1, and
characterized the resulting cells in vitro and in vivo. As
expected, Dkk-1 expression reduced the cells’ capacity for
osteogenic differentiation in vitro and in vivo, but it also
increased proliferation, resistance to metabolic stress and the
capacity for osteolytic tumorigenesis in vivo. These observa-
tions were attributed to upregulation of the stress response
enzyme and cancer stem cell marker aldehyde-dehydro-
genase-1 (ALDH1). The results herein support a mechanism
whereby Dkk-1 enhances resistance of OS cells to stress by
tipping the balance of Wnt-signaling in favor of the Jun-
mediated noncanonical Wnt pathways. In turn, this results in
the activation of RhoA, JNK, and transcriptional activation of
ALDH1 through Jun-responsive promoter elements. These
data not only support the targeting of Dkk-1 to prevent and
treat osteolytic bone lesions but also to deplete stress-
resistant tumor cells.
Results
Transfection of MOS-J cells. Full-length cDNA encoding
the human Dkk-1 gene was cloned into pLenti6.1 and
orientation was confirmed. Lentiviral transduction using
standard protocols resulted in an unsatisfactory yield of
transductants (less than 1%). In order to achieve stable gene
expression at higher yields, murine MOS-J cells were
transfected with plasmids encoding Dkk-1 or control vector
by nucleofection. Fluorescently labeled control and Dkk-1-
expressing sublines were generated by lentiviral transduction
of a construct constitutively expressing dsRedMito. Hereafter,
Dkk-1-expressing MOS-J cells are referred to as MOSJ-Dkk1
cells and controls will are referred to as MOSJ-pLenti cells.
Effect of Dkk-1 overexpression on MOS-J cells
in vitro. To confirm that Dkk-1 was secreted from the
MOSJ-Dkk1 cells, it was measured in conditioned media by
ELISA. A time-dependent increase of Dkk-1 in MOSJ-Dkk1
supernatants was observed, which reached a plateau of
3mg/ml after 7 days, indicative of steady-state production and
degradation of Dkk-1. Although there is 30% cross-reactivity
between human and murine Dkk-1 protein in this assay, no
Dkk-1 could be detected from control MOSJ-pLenti cells
(Figure 1a). Our group has reported that Dkk-1 has a
transient role in cell-cycle initiation in MSCs,18 and we
observed a similar effect on MOSJ-Dkk1 cells. However,
whereas the cell-cycle promoting effect of Dkk-1 in MSCs is
transient and rapidly downregulated as cells expand, it was
constitutively active in the case of MOSJ-Dkk1 cells, resulting
in faster expansion of cultures when compared with
the control cell line (Figure 1b). This was confirmed by
5-ethynyl-20-deoxyuridine (EdU) incorporation (Supplemen-
tary Figure S1a).
In order to examine whether the secreted Dkk-1 can
effectively disrupt cWnt-signaling in an autocrine manner,
cytosolic b-catenin levels were assessed by immunoblotting.
In MOSJ-Dkk1 cells, cytosolic and nuclear b-catenin levels
were diminished, suggesting that Dkk-1 is functionally active
and triggers its degradation consistent with inhibited cWnt-
signaling (Figure 1c, Supplementary Figure S1b).
In osteoprogenitors, cWnt-signaling positively regulates
osteogenic differentiation.18–20 Therefore, MOSJ-Dkk1 cells
would be expected to possess impeded osteogenic capacity
when compared with controls. To explore the differentiation
capacity of MOSJ-Dkk1 and MOSJ-pLenti cells in vitro, we
performed alkaline phosphatase (ALP) assays on cultures in
the presence of osteogenic factors, ascorbic acid and
b-glycerophosphate.21 Control MOSJ-pLenti cells exhibited
a relatively high level of ALP activity that could not be
substantially elevated by osteogenic supplementation. The
nonstimulated ALP activity in MOSJ-Dkk1 cells was approxi-
mately 20% of the controls, but, in this instance, it could be
enhanced to 50% of the MOSJ-pLenti levels by osteogenic
supplementation (Figure 1d). Next, we examined whether the
MOSJ lines had the capacity to adopt a mineralizing
phenotype by adding dexamethasone to the media.22
Dexamethasone-treated MOSJ-pLenti cells formed a miner-
alized monolayer within 2 weeks, but in accordance with our
previously published data6 this was completely ablated in
MOSJ-Dkk1 cells, presumably due to the inhibitory effects of
Dkk-1 (Figure 1e). These data therefore demonstrate that
Dkk-1 has the expected osteo-inhbitory effect in vitro. During
the mineralization studies, we observed that upon extended
confluency, MOSJ-pLenti monolayers frequently exhibited
areas of detachment and cell death that did not occur in the
MOSJ-Dkk1 cultures. This apparent culture instability could
be observed with the otherwise contact-inhibited parental cell
line, too, as previously reported.17
The phenomenon was investigated in more detail by
observing confluent cultures in the absence of osteogenic
supplementation. After extended confluency, under otherwise
stable conditions and frequent media changes, many of the
MOSJ-pLenti control cells showed classical signs of apoptosis
and died (Figure 1f, Supplementary Figure S2). In contrast,
the MOSJ-Dkk1 cells not only survived this challenge, forming
and maintaining a stable confluent monolayer, but also
continued to undergo frequent cell divisions that could be
observed above the plane of the monolayer (Figure 1f,
Supplementary Figure S2).
To quantify these observations, we performed cell-
cycle and viability assays on post-confluent cultures. The
measurements confirmed qualitative observations, in that a
greater proportion of MOSJ-Dkk1 cells were actively cycling
compared with controls even after 7 days of post-confluence
(Figures 2a and b). In contrast, a greater proportion of MOSJ-
pLenti cells accumulated in G0/G1 phase. In parallel with an
increased rate of mitosis, the MOSJ-Dkk1 cells were more
resistant to apoptosis as demonstrated by a decrease in the
proportion of AnnexinV-positive cells when compared with
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MOSJ-pLenti cells (Figures 2c and d). In contrast, the
MOSJ-pLenti controls alternated between periods of
apoptosis and periods of expansion where the empty
areas were repopulated. This is illustrated by a slight increase
in the number of cells in S-phase at day 7 post confluency
(Figure 2b).
These observations suggest that Dkk-1 not only has
profound effects on the differentiation and expansion capacity
of MOS-J cells but it also exerts a protective effect. To further
examine this apparently novel characteristic of Dkk-1, we
performed microarray analyses of confluent cultures of
MOSJ-Dkk1 and -pLenti cells. Among the most differentially
regulated genes were two aldehyde-dehydrogenase 1
(ALDH1) isoenzymes commonly associated with a pro-
survival phenotype. ALDHs are a family of detoxifying
enzymes, responsible for the metabolism of destructive free-
radicals that occur through the oxidation of lipids, resulting in
improved survival.23,24 The transcription of ALDH1A1 and
ALDH1A7 was profoundly upregulated on the microarrays
(73- and 10-fold, respectively), and this was confirmed by
quantitative RT-PCR (qRT-PCR) (Figure 2e). ALDH1 activity
in MOSJ-Dkk1 cells was also measured by using an Aldefluor
assay. Approximately 7% of the MOSJ-pLenti population was
ALDH-positive, with a signal above diethylaminobenzalde-
hyde (DEAB)-inhibitor-treated background levels, whereas
26% of the MOSJ-Dkk1 cells were positive by this definition.
Upon more detailed inspection of the profiles, however, we
noted a complete shift in the fluorescence intensity of MOSJ-
Dkk1 cells that was not evident with MOSJ-pLenti, suggesting
that all MOSJ-Dkk1 cells harbored DEAB-sensitive ALDH
activity (Figure 2f).
ALDH has been reported to provide protection against
chemical and environmental stress, especially in cancer stem
cells (CSCs). We therefore speculated that ALDH was
responsible for the enhanced MOSJ-Dkk1 viability. To explore
the role of ALDH in resistance to environmental stress, MOSJ-
Dkk1 cells were exposed to ALDH inhibitors chloramphenicol
(CP)25 or DEAB26 and subjected to periods of post-confluent
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Figure 1 Characterization of MOSJ-Dkk1 cells. (a, b) MOSJ-Dkk1 cells secrete human Dkk-1 into the supernatant (a) and have a growth advantage over MOSJ-pLenti
control cells (b) See also Supplementary Figure S1a. (c) Immunoblot (above) demonstrating reduced levels of cytosolic b-catenin in MOSJ-Dkk1 cells
and immunocytochemistry for b-catenin (below) demonstrating reduced nuclear levels (bar¼ 10mm). See also Supplementary Figure S1b. (d) ALP activity is inhibited in
MOSJ-Dkk1 cells compared with pLenti controls, but it can be partially recovered by osteogenic supplementation of the media. Cells were cultured in the absence ( ) or
presence (þ ) of osteogenic supplements, and ALP activity was measured by colorimetric assay after 8 days. (e) In contrast to MOSJ-pLenti controls, no calcium deposits
were evident in osteogenic cultures of MOSJ-Dkk1 stained with Alizarin Red S after 15 days. (f) MOSJ-Dkk1 cells maintain monolayers even after prolonged confluency,
whereas pLenti controls undergo apoptosis and detach in large patches. See also Supplementary Figure S2. All experiments were performed in triplicates. Data are
means±S.D. *Po0.05, ***Po0.001 (ANOVA, Tukey post test). Bars¼ 100mm
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culture. Although untreated controls survived 20 days with no
significant attrition, there was a dose-dependent cell-death in
cultures receiving CP or DEAB (Figures 2g and h). These
results support the role of ALDH in maintaining stress
resistance by MOSJ-Dkk1 cells, also suggesting the intriguing
possibility that Dkk-1 had initiated a CSC-like phenotype.
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Dkk-1 enhances ALDH1 expression through activation
of JNK. To test our hypothesis that, Dkk-1 had induced
ALDH expression, we performed RNAi-mediated Dkk-1
knockdown experiments. Using transient siRNA transfec-
tions in vitro, Dkk-1 levels in the supernatant of MOSJ-Dkk1
cultures could be substantially reduced (Figure 3a). After 2
days, ALDH1A1 and 1A7 transcription was measured by
qRT-PCR and found to be downregulated supporting a direct
link between Dkk-1 activity and ALDH expression
(Figure 3b). To test whether this phenomenon occurred in
human OS, two cell lines (SAOS and MG63) known to
secrete Dkk-1 were subjected to Dkk-1 blockade (Figure 3a).
When Dkk-1 expression was inhibited, ALDH1A1 transcrip-
tion was reduced in each case (Figure 3b). ALDH1A7
transcription was not determined due to the absence of its
expression in human cells. Interestingly, we noted that, with
the exception of SAOS cells, the cell lines that received
Dkk-1 blocking RNAi had diminished viability and overall cell
recovery when compared with cultures that received
scrambled RNAi (Supplementary Figure S3a).
The inverse correlation between ALDH1 expression and
cWnt-signaling was explored further by pharmacological
modulation. To dismiss the possibility of transfection-induced
artifact, or that Dkk-1 was acting on a pathway unrelated to
cWnt, we attempted to mimic the effects of Dkk-1 in the
parental MOS-J cells with small molecule inhibitors. For this
purpose, we utilized CT03477, a small molecule reported to
block the interaction between b-catenin and TCF,27 and a
tankyrase inhibitor (TNKiIII) reported to inhibit the degradation
of Axin2 and accelerate degradation of b-catenin.28–30 MOSJ-
pLenti cells were cultured in the presence of 50mM H2O2 for 2
days or for 20 days in the presence of the agents. Although
concentration dependent, approximately twofold more cells
survived these conditions when CT03477 and TNKiIII were
added to cultures at the reported IC50s (Supplementary Figure
S3b). Furthermore, both agents caused upregulation of
ALDH1A1 and ALDH1A7 (Figure 3c).
We then tested several GSK3b-inhibitors in order to
re-establish cWnt-signaling and potentially block the expre-
ssion of ALDH. After treating MOSJ-Dkk1 cells with 7-AIPM,
LiCl and BIO for 5 days, we observed a reduction in
ALDH mRNA levels while upregulating Axin2, suggesting
that re-establishment of cWnt activity can reverse the
Dkk-1-induced stress response (Figure 3d).
Dkk-1 activity and cWnt-inhibition have been reported to
induce a shift from canonical to noncanonical Wnt (ncWnt)
signaling, resulting in upregulation of JNK activity,31–34 and
this process has been reported to increase malignancy
of prostate12 and hepatocellular carcinoma cell lines.35
As ALDH1A1 expression can be upregulated by Jun/AP-1
complexes on the ALDH1A1 promoter,36 we speculated that
Dkk-1 might upregulate ALDH expression by promoting
ncWnt/JNK signaling. To test this hypothesis, MOSJ-Dkk1
cells were exposed to AP-1 inhibitors nordihydroguaiaretic-
acid (NDGA) and curcumin. Exposure to either inhibitors
reduced expression of ALDH1A1 and also ALDH1A7
(Figure 3e). Furthermore, immunoblotting confirmed upregu-
lation of JNK phosphorylation (Figure 3f). Noncanonical Wnt-
signalling has been reported to activate JNK through the
Rac1/planar-cell-polarity (PCP) or the Ror2 receptor path-
ways via activation map-kinase-kinase-7 (MKK7).37 When
screened by PCR, we found Ror2 was not expressed
(Figure 3g) and MKK7 phosphorylation was not upregulated
(Supplementary Figure S3c), thus eliminating Ror2/MKK7 as
a potential mechanism. In contrast, MKK4 phosphorylation
was upregulated in MOSJ-Dkk1 cells with an associated
upregulation of phospho-p38. These data were expected
given that MKK4 phosphorylates both JNK and p38, whereas
MKK7 is specific to JNK.38 The activation of MKK4 rather than
MKK7 suggested a PCP-like ncWnt pathway driven by Rac1/
RhoA signaling was responsible for the observed effects of
Dkk-1 on MOSJ-cells.39 In support of this interpretation, we
found the PCP-pathway components Daam1 and RhoA40
to be transcriptionally upregulated in MOSJ-Dkk1 cells
(Figure 4a). We were also able to demonstrate that treatment
of MOSJ-Dkk1 cells with a RhoA inhibitor reduced JNK
phosphorylation levels (Figure 4b) and subsequently Aldh1A1
and –1A7 transcription (Figure 4c). Together, the data
indicate that ALDH1 is upregulated by a JNK/PCP-like
pathway when cWnt activity is blocked by Dkk-1 (Figure 4d).
To further confirm a role for JNK and ALDH in supporting
OS cell survival, parental MOS-J cells were transfected with
constructs encoding constitutively expressing human c-Jun or
ALDH1A1. After transfection, the cells were subjected to post-
confluence for 6 days and then analyzed by using flow
cytometric apoptosis assay. ALDH and c-Jun overexpression
resulted in a reduced proportion of apoptotic cells (Figure 5a).
An increase in the proportion of Aldefluor-positive cells was
also observed in cultures that transiently expressed the
ALDH1A1 and c-Jun constructs (Figure 5b).
Effect of Dkk-1 on the tumorigenicity of MOS-J cells. To
test the effects of Dkk-1 on MOS-J tumorigenicity in vivo,
1 106 dsRed-labeled MOSJ-Dkk1 or -pLenti cells were
injected paratibially into 8-week-old nu/J mice. Over a period
of 5–7 weeks, animals were observed for tumor development
using a fluorescence imaging system (Figures 6a and b).
The tumors in MOSJ-pLenti mice were barely detectable
Figure 2 MOSJ-Dkk1 cells have improved survival capability through upregulation of ALDH. (a) Cell-cycle analysis demonstrates that post-confluent MOSJ-Dkk1 cells
actively cycle with a substantial proportion of cells in S/G2/M phase, whereas the majority of MOSJ-pLenti cells remain in G0/G1 phase. (b) Quantification of data presented in
panel a. (c) Flow cytometric viability assays demonstrate that post-confluent MOSJ-Dkk1 cells are more viable than MOSJ-pLenti controls (lower left quadrants) and are more
resistant to apoptosis as demonstrated by a decrease in the proportion of Annexin V-positive cells (lower right quadrants). (d) Quantification of data presented in panel c. Data
were analyzed with t-test after arcsine transformation and means±S.D. are displayed. **Po0.01. (e) Transcription of ALDH isoenzymes 1A1 and 1A7 is upregulated in
MOSJ-Dkk1 cells when measured by microarray or qRT-PCR. (f) ALDH1 enzyme activity in MOS-J cells was confirmed by using the Aldefluor assay. Background fluorescence
levels were defined by treatment with the ALDH inhibitor DEAB. Note that all MOSJ-Dkk1 cells harbor DEAB-sensitive ALDH activity resulting in a shift in fluorescence
intensity. This shift is not evident with MOSJ-pLenti cells where only a subpopulation is ALDH-positive. Representative images of three independent experiments are shown.
(g, h) The protective effect of ALDH could be antagonized in a dose-dependent manner by treatment with inhibitors chloramphenicol (g) and DEAB (h). All experiments were
performed in triplicates. Data were analyzed with ANOVA and Tukey post test. Means±S.D. are displayed. *Po0.05, **Po 0.01, ***Po 0.005
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until 7 weeks, when single circumscribed nodules could be
identified. In contrast, MOSJ-Dkk1 cells generated tumors
that became visible after 3 weeks and were readily
detectable as diffuse and extensive multi-lobular structures.
Generally, animals that received MOSJ-Dkk1 cells had to be
euthanized after week 5 because tumors reached the limits
Figure 3 Inhibition of cWnt by Dkk-1 results in increased ALDH expression by activating ncWnt-signaling and JNK. (a) Treatment of MOSJ-Dkk1 or human OS cell lines
(SAOS and MG63) with anti-Dkk-1 siRNA reduces Dkk-1 secretion when media is measured by ELISA (see also Supplementary Figure S3a). (b) Reduced Dkk-1 secretion
results in transcriptional downregulation of ALDH isoforms. (c) Inhibition of cWnt-signaling in MOSJ-pLenti cells with a b-catenin antagonist (CCT036477) or a tankyrase
inhibitor (TNKiIII) causes upregulation of ALDH transcription and improved post-confluent viability (see also Supplementary Figure S3b). (d) Re-establishing cWnt-signaling in
MOSJ-Dkk1 cells with inhibitors of GSK3b causes transcriptional inhibition of ALDH1A1 and -1A7 while upregulating AXIN2, a marker of cWnt-signaling. (e) AP-1 inhibitors
NDGA and curcumin reduce ALDH1A1 and -1A7 transcription, demonstrating that expression of the enzymes is regulated by the Jun transcription factor. (f) Western blots
demonstrating that MOSJ-Dkk1 cells have elevated levels of phosphorylated MKK-4, p38 and JNK but not MKK7 (see Supplementary Figure S3c). (g) absence of Ror2
receptor expression in MOS-J cells excludes this pathway. cDNA from E12.5 mouse embryos was used as positive control. All experiments were performed in triplicates.
Expression levels were compared with vehicle-treated cells. Data were analyzed with t-test and means±S.D. are displayed. *Po0.05, **Po0.01, ***Po0.005
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of the institutional tumor burden policy of 1 cm3. Control
animals were maintained for the full 7-week duration.
Hindlimbs of the mice were scanned using mCT to assess
bone involvement and measure tumor volume. The scans
indicated that control MOSJ-pLenti cells formed radio-dense
tumor nodules in the soft tissue that exhibited minimal
involvement with the host bone (Figure 6c). In contrast,
MOSJ-Dkk1 tumors were much larger and caused lytic bone
destruction that was particularly evident in the fibulas
(Figure 6d). As such, fibulas had a reduced proportion of
mineralized tissue when analyzed volumetrically (Figure 6j).
When visualized by mCT (Figures 6e–h) and histology
(Figure 7), MOSJ-Dkk1 cells had infiltrated into the host tissue
to the extent that prohibited volumetric measurement of
tumors. Therefore, an indirect method was employed to
estimate the volumes of the tumor (see Supplementary
Materials and Methods). In brief, a ROI was defined for each
limb where the proximal and distal limits of the tumor were
defined (Figure 6l). The total tissue volume within the ROI was
then calculated and compared with an anatomically equiva-
lent ROI in the unaffected contralateral limb. By this method,
excess volume contributed by the tumor and stroma could
be ascertained and, as a result, MOSJ-Dkk1 tumors were
found to be significantly larger than MOSJ-pLenti controls
(Figure 6i). Although the longitudinal dimensions were greater
in MOSJ-Dkk1 tumors (Figure 6l), the volumes of the
corresponding contralateral ROIs did not differ significantly
(Figure 6i). Histomorphometric analysis showed a reduction in
trabecular thickness of MOSJ-Dkk1-affected tibias (Figure 6k)
and an increased inner diameter (Supplementary Figure S4),
in accordance with the more osteolytic phenotype of MOSJ-
Dkk1 cells.
To characterize the pathology in more detail, serial sections
were stained with trichrome and inspected by a clinical
pathologist with expertise in OS. When examined histologi-
cally, MOSJ-pLenti cells formed small ossified nodules that
displaced the surrounding muscle tissue but did not substan-
tially affect the bone (Figures 7a–d). In contrast, MOSJ-Dkk1
tumors exhibited aggressive growth behavior, lytic bone
involvement and destructive soft tissue invasion (Figures
7e–h). Of particular note was the lack of differentiation of
MOSJ-Dkk1 tumors, resulting in homogeneous masses of
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Figure 4 Involvement of the RhoA pathway. (a) Transcription of Daam1 and Rhoa is upregulated in MOSJ-Dkk1 cells when measured by PCR array or qRT-PCR.
(b, c) Treatment of MOSJ-Dkk1 cells with a RhoA inhibitor reduces JNK phosphorylation levels after 2 h (b) and subsequently Aldh1A1 and –1A7 transcription levels (c).
(d) The proposed PCP-like pathway suggesting that ALDH is activated by ncWnt-mediated modulation of JNK. Data were analyzed with t-test and means±S.D. are
displayed. *Po0.05, ***Po0.005
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spindle-like cells, a phenomenon usually associated with
more malignant OS. In contrast, MOSJ-pLenti tumors
exhibited areas of bone, adipose and cartilage differentiation
consistent with the underlying osteochondrosarcoma pheno-
type (Figures 7d and h). The same growth pattern was evident
in the femurs (Supplementary Figure S5).Taken together,
these results demonstrate that MOSJ-Dkk1 tumors were
larger and substantially more destructive than their MOSJ-
pLenti controls.
Discussion
Herein, we explored the effects of a single constitutively
expressed gene, human Dkk-1, on the growth of the murine
OS cell line MOS-J. Our most striking observation was the role
of Dkk-1 in enhancing proliferation and survival of MOSJ-
Dkk1 cells when subjected to metabolic stress. These results
were unexpected, given the classical role of cWnt in driving
oncogenesis in numerous tissues.41 Dkk-1 expression
resulted in the activation of JNK, which in turn caused
transcriptional activation of two isoenzymes of the ALDH1
family. Given the inhibitory effects of NGDA and curcumin and
a recent report that ALDH1A1 expression is activated by Jun
transcription factors, the results suggest that JNK activates
Jun/AP-1 complexes in the ALDH1 promoters.
Our data provide a novel explanation for the various and
sometimes contradicting effects of Dkk-1 and Wnt-signaling
on bone tumor biology. They suggest that catastrophically
high levels of cWnt-inhibitor shift the balance in favor of
ncWnt-signaling. Mechanisms that explain the shift between
cWnt- and ncWnt-signaling are yet to be comprehensively
characterized, but our data are in agreement with a recently
published study by Killick et al.42 who report a link between
Dkk1 and PCP-JNK in a model of Alzheimer’s disease.42 The
downstream effect, as initially observed by Matushansky et al.
and Thudi et al., is activation of JNK signaling and the initiation
of a more malignant phenotype.11–12 Our observations are
similar in that we confirm that, through JNK activation, Dkk-1
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Figure 5 Constitutive expression of c-Jun or ALDH mimics the effect of Dkk-1 in parental MOS-J cells. Plasmid constructs encoding human ALDH1A1 or c-Jun were
transfected into parental MOSJ cells and subjected to post-confluent tissue culture. (a) Flow cytometric apoptosis assays demonstrating a reduced proportion of apoptotic cells
in cultures that received ALDH1A1 or c-Jun cDNA when compared with controls harboring an equivalent vector control. Data were analyzed by ANOVA and Tukey post test
after arcsine transformation and means±S.D. are displayed. **Po0.01, ***Po0.005. (b) Aldefluor assay shows increased ALDH activity of transfectants when compared
with the parental cells
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exacerbates the malignancy of tumor cells. However, they are
novel in proving that this effect occurs through enhanced
resistance to metabolic stress through ALDH1 rather than
dysregulation of mitosis and that the mechanism responsible
is likely to be through a RhoA/Rac-dependent PCP-like ncWnt
pathway.
ALDH1, a marker previously associated with the CSC-
phenotype,43–44 was recently found to have a role in drug
MOSJ-pLenti MOSJ-Dkk1
Figure 6 Tumor formation in vivo. Representative images of tumors resulting from the injection of dsRed-labeled MOSJ-pLenti- or MOSJ-Dkk1 cells in nude mice.
(a, b) MOSJ-pLenti tumors form circumscribed nodules after 7 weeks (a), whereas MOSJ-Dkk1 cells generate larger tumors with extensive multi-lobular structures
(b, 5 weeks). Bars: 1cm. (c, d) Reconstructions of mCT scans from the affected tibias and fibulas. MOSJ-pLenti cells formed radio-dense tumor nodules in the soft tissue and
exhibited minimal involvement with the host bone (c). MOSJ-Dkk1 tumors caused lytic bone destruction and remodeling that was most evident in the fibulas (d). (e, f) Axial
reconstructions of contrast stained scans of MOSJ-pLenti (e) and MOSJ-Dkk1 (f) harboring limbs. (g, h) Three dimensional reconstructions of mCT whole limb scans after
contrast staining demonstrate the extent of soft tissue involvement in MOSJ-Dkk-1 tumors (h) compared with pLenti-MOSJ harboring limbs that have a normal appearance
(g). (i) Total tissue volume in ROIs containing the tumor as compared with an anatomically equivalent ROI on the unaffected contralateral side. The volume of tissue in the
MOSJ-pLenti ROI is equivalent to the contralateral limb, whereas, in the case of MOSJ-Dkk1 tumors, the affected limbs are approximately twofold larger than the contralateral
side. Note also that volumes between MOSJ-pLenti and -Dkk1 contralateral limbs do not significantly differ in spite of the slightly increased length of the MOSJ-Dkk1 ROI.
(j) Volumetric calculation of bone in the fibulas confirmed increased osteolysis in MOSJ-Dkk1 recipients. (k) The trabecular thickness (Tr. Th.) of MOSJ-Dkk1 affected tibias is
decreased, suggesting a more osteolytic phenotype. See also Supplementary Figure S4. (l): Proximal/distal involvement of tumors as a measure of the length of the limb
affected by tumor tissue. Results displayed as box and whisker plots with the boxes representing the 25–75th percentiles, the center line representing the median, and the
whiskers representing the full range of data. (n¼ 4); *Po0.05, **Po0.01, ***Po0.001, ns P40.05
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resistance and enhanced survival in OS cells.45–46 Our
observations that Dkk-1 induces expression of ALDH1A1
and ALDH1A7 are consistent with this hypothesis. It should be
noted, however, that, in human OS, the effect is probably
mediated through ALDH1A1 only, given that ALDH1A7 is not
present in human cells, even though it shares substantial
sequence similarity with ALDH1A1.47
In a study of soft tissue sarcomas, high Dkk-1 levels
correlated with poorly differentiated and more aggressive
sarcomas.48 Our results support these observations, demon-
strating that Dkk-1 alone can convert a relatively benign and
well-differentiated OS cell line17 into a more aggressive and
primitive form.49 Depending on the underlying tissue of origin,
cancers with high levels of Dkk-1-expression have been
reported both as being pro- and antimetastatic.50 Although
being more aggressive, none of the animals showed signs of
metastasis when we examined the lungs. Nevertheless,
in many animal models of metastatic OS disease, the primary
tumor has to be excised to artificially extend the time window
needed for lung metastases to develop.51 As the MOSJ-Dkk1
variant turned out to be prohibitively aggressive, one could
speculate that any existing lung metastases were too small to
observe before the ethical end point. Therefore, extra work is
required to explore the role of Dkk-1 in OS metastasis.
With the exception of tibial trabecular thickness, medullary
canal diameter and fibula volume, differences in the quality of
bone adjacent to the tumors were mostly qualitative, with the
replacement bone around MOSJ-Dkk1 tumors consisting of
cancellous, poor quality tissue. This is likely caused by the
mixed osteoclastic/osteoblastic nature of OS and the rapid
remodeling that occurs. Secondary bone tissue is likely to be
susceptible to risk of pathologic fractures, and it also provides
MOSJ-pLenti MOSJ-Dkk1
Figure 7 Histology of tumors and bone lesions. Serial sections of MOS-J tumors were stained with hematoxylin and eosin (a, e) and trichrome (b–d, f–h). MOSJ-pLenti
cells form small ossified nodules and tumors that displaced the surrounding muscle tissue and did not substantially affect the bone surface (a). Areas of cartilage, bone and fat
differentiation consistent with the underlying osteochondrosarcoma phenotype are evident (b–d). In contrast, MOSJ-Dkk1 tumors exhibited aggressive growth behavior (e, f),
soft tissue invasion, and lytic bone involvement (arrows, g). Note the complete lack of differentiation resulting in highly homogeneous masses of more primitive spindle-like
cells (h). See also Supplementary Figure S5. Bars: 1 mm
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a superior substratum for osteoclast activity. Indeed, the total
bone area adjacent to the MOSJ-Dkk1 tumor was densely
populated by osteoclasts.
In this study, we demonstrate that expression of a Wnt-
inhibitor, Dkk-1, is capable of activating a potent growth and
survival pathway in OS cells. The effects of Dkk-1 on cellular
physiology were multi-faceted, involving decreased differen-
tiation potential, increased proliferation and enhanced osteo-
lytic capacity. Surprisingly, Dkk-1 also triggered a potent
survival response mediated by ncWnt/JNK activation. This in
turn resulted in expression of the detoxifying enzyme and
CSC-marker ALDH1, equipping the cells with enhanced
resistance to metabolic stress. Resultant tumors were large,
poorly differentiated and highly destructive.
Strategies to judiciously re-establish the cWnt axis through
pharmacological inhibition of GSK3b,52 immunosequestration
of Dkk-153,54 or direct inhibition of ALDH activity with
chloramphenicol or disulfiram25 could lead to promising
adjunct therapies for OS and possibly other types of bone
tumor. These strategies are expected to reduce the CSC-pool
and render tumors more susceptible to conventional anti-
mitotic therapies.
Materials and Methods
Tissue culture. (See Supplementary Materials and Methods for details) We
expanded the murine OS cell line MOS-J17 (The Jackson Laboratory, Bar Harbor,
ME, USA) in medium consisting of aMEM, 10% fetal bovine serum (FBS), 100
units/ml penicillin G and 100mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA).
Cell numbers and viability were assessed using trypan blue staining (GIBCO/
Invitrogen). Human OS cell lines SAOS and MG63 were acquired from the
American Type Culture Collection (Manassas, VA, USA) and cultured in the same
manner as MOS-J cells.
Transfection of MOS-J cells. In order to generate a humanized mouse
model of Dkk1-induced bone disease, we introduced the human Dkk-1 gene into
MOS-J cells via lentiviral particles produced using the pLenti6/V5 Directional
TOPO Cloning Kit and ViraPower Lentiviral Expression System (Invitrogen). For
nonviral transfection, human Dkk-1 cDNA was cloned into the pLenti6.1 plasmid
(Invitrogen) by standard methods.
Aldefluor staining. To confirm ALDH activity in the cells, one million cells
were labeled by the Aldefluor assay kit (Aldagen, Durham, NC, USA) following the
manufacturer’s recommendations and analyzed using a FC500 flow cytometer
(Beckman Coulter, Miami, FL, USA). Cells treated with the ALDH-inhibitor
diethylaminobenzaldehyde (DEAB) served as an internal control for identifying
background signals.
Inhibition of GSK3b. In order to re-establish cWnt-signaling, MOSJ-Dkk1
cells were treated with GSK3b inhibitors of varying reported specificities 7-AIPM,
6-bromoindirubin- 30-oxime (BIO; both Calbiochem EMD Millipore, Billerica, MA,
USA) and LiCl (Alexis Biochemicals, San Diego, CA, USA) as published earlier.52,55
Animal care and use. All animal experiments were performed in accordance
with animal use protocols approved by the Tulane University and Scott & White
Hospital Animal Care and Use committees. Female 8-week-old nu/J mice were
acquired from Jackson Laboratories. Mice were housed in groups of four per cage
under specific pathogen-free conditions. They were allowed to access sterile
standard mouse chow and water ad libitum.
Orthotopic implantation of MOS-J cells and OS model. Under
isoflurane anesthesia, one million dsRed labeled MOSJ-Dkk1 or MOSJ-pLenti
cells were injected against the posterior surface of the tibia in 100ml of plasma
(Sigma-Aldrich, St. Louis, MO, USA) containing thromboplastin (Bio/Data
Corporation, Horsham, PA, USA). To follow tumor growth, animals were imaged
using a Maestro fluorescence imaging system (Perkin Elmer, Waltham, MA, USA)
and software (version 2.6, Cambridge Research & Instrumentation, Hopkinton,
MA, USA). After 7 weeks or when institutional tumor burden criteria were met,
mice were euthanized by terminal exsanguination under deep anesthesia. Animals
were perfused with excess PBS and formalin, and legs and lungs were collected.
Histology. After 48 h fixation in 10% neutral buffered formalin, tissues were
transferred to Carson’s fixative and processed as described elsewhere.21
Micro-CT (lCT). Fixed hindlimbs were scanned using a specimen mCT
scanner (Skyscan 1174, Bruker-microCT, Kontich, Belgium) set at 50 kV and
800mA to perform bone histomorphometry, assess bone damage and measure
tumor volume as described earlier.56
Statistical analysis. Statistical tests and data plotting were performed using
GraphPad Prism (ver 5.00 for Windows, La Jolla, CA, USA). ELISA standard
curves and values were calculated with ReaderFit (http://www.readerfit.com).
Data involving ratios were statistically tested on arcsine-transformed data and
post-analyzed by Tukey’s or Dunnett’s method. Single means were compared
using t-test. Data were regarded significant, if P values wereo0.05.
Microarray data have been deposited in NCBI’s Gene Expression Omnibus and
are accessible through GEO Series accession number GSE43112 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43112).
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